Septerna (SEPN) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.57

Estimate

-$0.40

Surprise

-43.7%

Revenue (period 2026-09-30)

$18.9M

Score today

4.8/10

Revenue source: xbrl.

Septerna (SEPN) reported a wider loss than forecast — adjusted EPS of -$0.57 against the -$0.40 estimate (a 43.7% shortfall).

• Stifel Maintains Buy on Septerna, Raises Price Target to $60 — benzinga, 2026-11-10
• Septerna, Inc. Reports Third Quarter 2026 Financial Results and Business Progress — fiscal.ai, 2026-11-09
• Septerna Q3 EPS $(0.57) Misses $(0.45) Estimate, Sales $18.881M Miss $20.780M Estimate — benzinga, 2026-11-09

TrendMatrix currently rates SEPN Sell at 4.8/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -43.7% surprise compares with a +11.5% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$50.80

Stop

$47.24

Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$2.37B

P/E (fwd)

-26.1

52-week range

$17.98–$51.10

Off 52-week high

0.6%

RSI (14)

81

Volume vs avg

0.65×

Score today

4.8/10